🇺🇸 FDA
Patent

US 9872855

(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

granted A61KA61K31/421A61K45/06

Quick answer

US patent 9872855 ((2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid) held by Theravance Biopharma R&D IP, LLC expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/421, A61K45/06, A61K47/12, A61K9/4816